tirzepatide and binge eating disorder GLP-1s may reduce similar behaviours in people living with obesity, suggests the most comprehensive systematic review and meta-analysis to date, published in eClinicalMedicine. Find out more 👉 http://spkl.io/61897yUsZ Figure Binge Eating and Calorie Deficit:

Alternatives might include switching to a different GLP-1 medication (some patients tolerate one better than another despite similar mechanisms), reducing the maintenance dose to a level that produces fewer GI effects while still providing benefit, or transitioning to tirzepatide or another agent in the class

Products are intended for qualified research and laboratory applications only

This structured approach helps patients stay consistent, make informed decisions, and adjust their plan when needed to keep weight loss moving in the right direction

Long-term cardiovascular outcomes data is pending (SURPASS-CVOT trial)